Core Viewpoint - The investor research event held by Tong Ren Tang Technology showcased the company's commitment to modernizing traditional Chinese medicine while maintaining its heritage and quality standards [1][2]. Group 1: Production and Innovation - The production line at Tong Ren Tang Technology employs automated and connected processes, ensuring efficiency and quality in the manufacturing of traditional Chinese medicine products [2]. - The company is focused on upgrading its production capabilities and implementing new technologies to create a modern intelligent manufacturing system for traditional Chinese medicine [2]. - The goal is to ensure that every pill produced meets high-quality standards and is traceable, embodying the spirit of Tong Ren Tang in a modern factory setting [2]. Group 2: Management Communication and Strategy - During the event, the management team, led by General Manager Zhang Chunyou, engaged in detailed discussions with investors regarding the company's operational strategy, product positioning, and future growth opportunities [3]. - The management emphasized the systemic development opportunities in the traditional Chinese medicine industry, driven by national health strategies and policies [3]. - Tong Ren Tang Technology aims to leverage its brand, technology, and quality advantages to deepen its focus on traditional Chinese medicine and explore new growth avenues in health management [3]. Group 3: Investor Relations - The research event served as a platform for enhancing investor relations, with the management team expressing the importance of transparent communication with investors [4]. - The company is committed to maintaining an open and inclusive investor relations ecosystem, reflecting its strategic determination and proactive approach in the industry [4]. - Continuous and transparent communication is seen as a vital bridge connecting the company with long-term value investors [4].

Core Viewpoint - The recent incident involving Antarctic krill oil with zero phospholipid content has tarnished the reputation of the "Tong Ren Tang" brand, highlighting ongoing issues with brand and trademark management within the Tong Ren Tang Group [1][3]. Group 1: Incident Overview - The Antarctic krill oil in question was produced by Anhui Habao Pharmaceutical and distributed by Beijing Tong Ren Tang (Sichuan) Health Pharmaceutical, which is not a subsidiary of the publicly listed Tong Ren Tang [3]. - The product used the "Tong Ren Tang" trademark, which is owned by the Tong Ren Tang Group, leading to public confusion and backlash against the listed company [3][4]. - The company clarified that it does not hold any equity or investment rights in the implicated Beijing Tong Ren Tang (Sichuan) Health Pharmaceutical [3]. Group 2: Brand Management Issues - The incident underscores the chaotic brand authorization within the Tong Ren Tang Group, which could lead to further issues if not addressed [5]. - The krill oil product prominently featured the "Beijing Tong Ren Tang" label, raising concerns about brand misuse and the similarity to the "Tong Ren Tang" double-dragon trademark [5][6]. - The Tong Ren Tang Group controls over 500 enterprises and has a complex business structure, which complicates product quality and brand management [6]. Group 3: Historical Context - Tong Ren Tang was founded in 1669 and has a long history of serving the imperial court, which has contributed to its prestigious reputation [7]. - The brand has faced legal challenges in the past, including a notable trademark infringement case with Tianjin Tong Ren Tang, which has led to ongoing litigation and eventual acquisition plans [9][10]. - Multiple entities using the "Tong Ren Tang" name across different regions complicate brand management and increase the risk of brand dilution [12].

Core Insights - The investor research event held on December 16 at Tong Ren Tang Technology Development Co., Ltd. showcased the company's modernization efforts and commitment to traditional craftsmanship in the context of its transformation [1] Group 1: Production and Technology - The production line at Tong Ren Tang employs automated and connected processes, ensuring a seamless workflow from pill production to packaging, highlighting the integration of traditional methods with modern technology [4] - The company aims to establish a modern intelligent manufacturing system for traditional Chinese medicine, ensuring that each pill maintains high quality and traceability [4] Group 2: Management Communication - During the event, the management team, led by General Manager Zhang Chunyou, engaged in detailed discussions with investors regarding the company's operational strategy, core product layout, capacity enhancement, and future growth potential [4] - The management emphasized the importance of transparent communication with investors to convey the company's cultural values, operational logic, and strategic planning [5] Group 3: Industry Context - The Chinese medicine industry is perceived to be entering a systematic development opportunity, supported by national health strategies and policies promoting traditional medicine [5] - Tong Ren Tang is positioned to leverage its brand, technology, and quality systems to deepen its engagement in the traditional medicine sector and explore new growth avenues [5]

Core Viewpoint - The concept of "food and medicine sharing the same source" is gaining popularity, leading to increased demand for health products, particularly ready-to-eat Ejiao products, driven by various consumer demographics including the elderly, women, and Gen Z [1][8]. Market Overview - The ready-to-eat Ejiao market in China is projected to reach a scale of 54.3 billion yuan in 2024, representing a year-on-year growth of 22.3%, accounting for 25% of the overall ready-to-eat health product market [1][8]. - Ready-to-eat Ejiao is produced through optimized formulations and improved processes, making it convenient for modern lifestyles [2][3]. Market Policies - Recent policies emphasize food safety and quality control across all stages of production, processing, and distribution of ready-to-eat Ejiao, promoting a shift towards standardized and high-quality industry practices [4][5]. Industry Chain - The upstream of the ready-to-eat Ejiao industry includes suppliers of key raw materials such as donkey hide, black sesame, walnuts, red dates, honey, and rock sugar, while the midstream consists of production companies, and the downstream includes various sales channels [6][7]. Current Development - The demand for ready-to-eat Ejiao is expanding beyond traditional consumers to include working professionals and younger generations, with consumption scenarios evolving to include daily snacks and gift-giving [8][9]. Competitive Landscape - The ready-to-eat Ejiao market is characterized by a concentrated competitive structure, dominated by two major players, Dong'e Ejiao and Fupai Ejiao, which control key raw material supplies and have established strong brand loyalty [10]. - Dong'e Ejiao reported a revenue of 3.051 billion yuan in the first half of 2025, with 93.2% of this coming from Ejiao and related products [11]. - Fupai Ejiao achieved a revenue of 2.104 billion yuan in 2024, marking a 5% increase, with over 40% of sales coming from non-Ejiao block products [12]. Future Trends - The ready-to-eat Ejiao product line is expected to diversify further, introducing more portable and snack-like options, while also targeting specific consumer needs such as prenatal nutrition and weight management [13]. - The international market for ready-to-eat Ejiao is anticipated to expand, initially targeting regions with high Chinese populations and gradually moving towards Western markets [13].

2025.12. 18 作者 | 第一财经 钱童心 "同仁堂"涉嫌磷虾油造假事件还在进一步发酵。北京同仁堂股份有限公司（同仁堂，600085.SH） 日前发布澄清公告称，同仁堂股份未直接或间接持有南极磷虾油相关报道中提及的四川健康药业任何 股权及投资权益，四川健康药业不属于自己下属子企业。北京同仁堂健康药业股份有限公司为北京同 仁堂（四川）健康药业有限公司的控股股东。 不过，对于同仁堂这种急于"撇清关系"的说法，相关律师认为，这是企业的"文字游戏"。"北京同仁 堂（四川）健康药业有限公司虽然不是上市公司北京同仁堂股份有限公司的子公司，但却是其关联公 司。"上海大邦律师事务所合伙人游云庭对第一财经记者表示，"两家公司相当于是叔侄关系，共同 的上级公司是商标权人北京同仁堂集团公司，虽然上市公司的下属公司没出问题，但整个品牌暴露在 风险之下。" 近日，上海市消保委对"同仁堂"相关磷虾油生产商安徽哈博药业有限公司和经销商北京同仁堂（四 川）健康药业有限公司进行约谈后，"四问同仁堂"。 上海市消保委提出，相关磷虾油产品极低的采购价也令人迷惑。该产品网上售价为69.9元一瓶，然 而产品供货价仅为3元多一瓶，也间接佐证了产 ...

Core Viewpoint - The incident involving "Tongrentang" and the alleged fraud related to krill oil is escalating, with the company attempting to distance itself from the implicated entities [1] Group 1: Company Response - Beijing Tongrentang Co., Ltd. clarified that it does not hold any equity or investment rights in Sichuan Health Pharmaceutical Co., Ltd., which is mentioned in the reports regarding krill oil [1] - The company emphasized that Beijing Tongrentang Health Pharmaceutical Co., Ltd. is the controlling shareholder of Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd., indicating a relationship but not direct ownership [1] Group 2: Legal and Regulatory Concerns - Legal experts suggest that the company's attempt to clarify its position may be seen as a "word game," as the relationship between the companies still exposes the brand to risks [1] - The Shanghai Consumer Protection Committee raised concerns about the suspiciously low procurement price of the krill oil, which sells online for 69.9 yuan per bottle while the supply price is only around 3 yuan, indicating potential fraud [2] Group 3: Market Implications - The Shanghai Consumer Protection Committee highlighted a broader issue of misleading practices in the health and nutrition product market, calling for action to eliminate such "routines" and create a trustworthy purchasing environment [2] - Concerns were raised about the responsibility of Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. in maintaining the commercial reputation of its parent company [2] Group 4: Product Quality and Responsibility - According to legal experts, if the sales of the krill oil were led by Sichuan Tongrentang, then it and its sales channels should be held accountable for the incident [3] - The social harm of the krill oil incident is significant, as products from subsidiary companies may vary in quality, leading to consumer confusion [3]

Core Viewpoint - The controversy surrounding the alleged fraud involving krill oil products linked to Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. continues to unfold, with the parent company, Beijing Tongrentang Co., Ltd., distancing itself from the issue, despite being associated with the implicated company [1][2]. Group 1: Company Relations and Responsibilities - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. is not a subsidiary of Beijing Tongrentang Co., Ltd. but is an affiliated company, raising concerns about brand reputation and accountability [1]. - Legal experts suggest that the relationship between the two companies indicates a shared responsibility for maintaining the brand's commercial reputation, despite the parent company's claims of ignorance regarding the fraud [2][3]. Group 2: Consumer Protection and Market Practices - The Shanghai Consumer Protection Committee has raised concerns about the suspiciously low procurement price of the krill oil products, which is significantly lower than the retail price, suggesting potential fraud involving the substitution of krill oil with fish oil extracts [2]. - The committee emphasizes the need for regulatory bodies to address consumer concerns and eliminate deceptive practices in the health product market, highlighting a broader issue of quality inconsistency among products from established brands [2]. - Legal experts assert that if the sales of the fraudulent products were led by Sichuan Tongrentang, the company and its sales channels should be held accountable for the incident [3].

Core Viewpoint - Beijing Tongrentang Health Pharmaceutical Co., Ltd. is facing a significant public relations crisis due to a product labeled as "99% high-purity Antarctic krill oil" that was found to contain zero phospholipids, raising serious concerns about product authenticity and quality control [1][3][5] Group 1: Incident Overview - The Shanghai Consumer Protection Committee conducted a market inspection revealing that the krill oil product, marketed with claims of "Chilean imported raw materials" and "1 capsule ≈ 100 krill," failed to meet the phospholipid content standards, showing a result of zero [1][3][5] - The manufacturer, Anhui Habao Pharmaceutical Co., admitted that the product did not contain Antarctic krill oil, while the distributor, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., avoided responsibility during discussions with the consumer protection committee [1][5][6] Group 2: Historical Context - This incident is not the first controversy for Tongrentang, with previous issues including the "honey scandal" in 2018 and other product quality concerns in subsequent years, highlighting ongoing challenges in quality control under a private label manufacturing model [2][11][12] Group 3: Financial Performance - Tongrentang's financial performance has been declining, with a reported revenue of 18.597 billion yuan in 2024, a 4.12% increase, but a net profit of 1.526 billion yuan, marking an 8.54% decrease, the first negative growth in five years [13][15] - The company's operating costs rose significantly, with a 10.70% increase in 2024, primarily driven by rising raw material costs, leading to a decline in gross margins across various product lines [15][16] Group 4: Brand Management Challenges - The brand is facing a trust crisis, compounded by frequent quality issues and a complex market presence with multiple entities using the Tongrentang name, leading to consumer confusion [12][16] - The company is under pressure to unify its brand and improve quality control while addressing historical issues and restoring consumer trust [16]

在今天的商业环境中，各大品牌面临的价格困境日益严峻。在各大电商与社交平台上，未经授权的低价、乱价、假冒商品悄然上架，持续侵蚀着品牌方多年 投入建立的高端形象与市场定位。核心经销商的利润空间与销售积极性被严重打击，"劣币驱逐良币"的现象时有发生。 这些困境的核心在于，品牌控价是一项需要专业法律知识、技术工具和系统策略支持的综合性工程，仅凭品牌一己之力难以周全应对。 品牌控价已远不止于简单的渠道管理，它直接关乎品牌资产、企业利润与可持续发展，是一场真正的战略核心保卫战。然而，许多品牌方在尝试自行管控 时，往往因方法不当陷入法律与市场的双重困境。 01 现实警示：价格失控带来的多重经营危机 价格体系一旦崩塌，首先冲击的是品牌的根本价值。价格是品牌定位最直观的体现，长期、混乱的低价会向消费者传递"产品不保值"、"价值低廉"的信号， 严重损耗品牌声誉，导致用户忠诚度下降。 更深层的危机在于渠道体系的瓦解。合规经销商的利益若因窜货、乱价行为得不到保护，其投入资源和遵守规则的动力将消失，最终可能导致核心销售渠道 流失，让整个市场陷入恶性价格战的混乱之中。 更为隐秘的风险是法律与数据的双重失守。市场上的假货、未授权商品可能使 ...

Core Viewpoint - The incident involving Beijing Tongrentang's Antarctic krill oil product has raised significant concerns about false advertising and quality control in the health supplement industry, leading to the product's removal from major e-commerce platforms [1][2][4]. Group 1: Product and Market Analysis - The product in question, marketed as "99% high purity Antarctic krill oil," was found to contain no actual krill oil, despite claims of 43% phospholipid content [4][7]. - The product was sold at a price of approximately 60 yuan per bottle, while the production cost was only between 3 to 3.7 yuan [7][9]. - The product's packaging prominently featured the "Beijing Tongrentang" name, which misled consumers regarding its authenticity and quality [4][11]. Group 2: Regulatory and Consumer Protection - The Shanghai Consumer Protection Committee conducted an industry evaluation that led to the discovery of the misleading claims and initiated a formal inquiry with the involved parties [4][7]. - The committee questioned the accountability of the distributor, Sichuan Health Pharmaceutical, which denied knowledge of the fraudulent practices, raising concerns about the integrity of the supply chain [7][11]. - The committee emphasized the need for better consumer protection and accountability in the health food sector, particularly regarding the marketing of functional foods [9][11]. Group 3: Brand Reputation and Industry Implications - The incident has put the reputation of the Tongrentang brand at risk, highlighting issues related to brand management and oversight of sub-brands [2][13]. - There is a growing concern about the prevalence of counterfeit and misleading products associated with the Tongrentang name, which could further damage consumer trust [15]. - This is not the first quality crisis for Tongrentang, as previous incidents have also raised questions about the company's quality control and brand management practices [15].